The global market for High Throughput Screening (HTS) is estimated at US$40.4 Billion in 2023 and is projected to reach US$45.3 Billion by 2030, growing at a CAGR of 1.6% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The evolution of HTS continues with technological and scientific advancements shaping its methodologies and increasing its impact and efficiency. The integration of artificial intelligence and machine learning enhances data analysis capabilities, allowing for a deeper interpretation of complex datasets. Innovations in assay technology, such as the adoption of microchip-based systems and nanoliter dispensing technologies, are refining the precision and reducing the resource requirements of screenings. The major drivers of growth in HTS include advancements in automation and robotics, the use of microfluidics and nanotechnology, and the increasing demand for personalized medicine, which relies on HTS for identifying unique biomarkers and developing tailored therapies. Moreover, the expansion of biologics and specialty pharmaceuticals, along with supportive regulatory environments and increased funding for drug discovery, are bolstering the adoption of HTS. Collaborations between academia and the pharmaceutical industry are also vital, facilitating knowledge exchange and enhancing the implementation of HTS technologies, particularly critical in responding to global health crises and the public demand for rapid development of effective medications.
The evolution of HTS continues with technological and scientific advancements shaping its methodologies and increasing its impact and efficiency. The integration of artificial intelligence and machine learning enhances data analysis capabilities, allowing for a deeper interpretation of complex datasets. Innovations in assay technology, such as the adoption of microchip-based systems and nanoliter dispensing technologies, are refining the precision and reducing the resource requirements of screenings. The major drivers of growth in HTS include advancements in automation and robotics, the use of microfluidics and nanotechnology, and the increasing demand for personalized medicine, which relies on HTS for identifying unique biomarkers and developing tailored therapies. Moreover, the expansion of biologics and specialty pharmaceuticals, along with supportive regulatory environments and increased funding for drug discovery, are bolstering the adoption of HTS. Collaborations between academia and the pharmaceutical industry are also vital, facilitating knowledge exchange and enhancing the implementation of HTS technologies, particularly critical in responding to global health crises and the public demand for rapid development of effective medications.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the HTS Consumables / Reagents segment, which is expected to reach US$16.9 Billion by 2030 with a CAGR of a 3.7%. The HTS Consumables/Reagents segment is also set to grow at 6.9% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $10.6 Billion in 2023, and China, forecasted to grow at an impressive 5.9% CAGR to reach $11.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global High Throughput Screening (HTS) Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global High Throughput Screening (HTS) Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global High Throughput Screening (HTS) Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Agilent Technologies, Inc., Aurora Biomed Inc., Axxam SpA, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 41 Featured):
- Agilent Technologies, Inc.
- Aurora Biomed Inc.
- Axxam SpA
- BD Biosciences
- Beckman Coulter Inc.
- Bio-Rad Laboratories Inc.
- BioTek Instruments Inc.
- BMG LABTECH GmbH
- Charles River Laboratories International Inc.
- Corning Inc.
- Danaher Corporation
- Evotec AG
- F. Hoffmann-La Roche Ltd.
- Genedata AG
- IntelliCyt® Corporation
- Luminex Corporation
- Molecular Devices Inc.
- Pall ForteBio LLC
- PerkinElmer Inc.
- Sigma-Aldrich Corp.
- Tecan Group Ltd.
- Thermo Fischer Scientific Inc.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agilent Technologies, Inc.
- Aurora Biomed Inc.
- Axxam SpA
- BD Biosciences
- Beckman Coulter Inc.
- Bio-Rad Laboratories Inc.
- BioTek Instruments Inc.
- BMG LABTECH GmbH
- Charles River Laboratories International Inc.
- Corning Inc.
- Danaher Corporation
- Evotec AG
- F. Hoffmann-La Roche Ltd.
- Genedata AG
- IntelliCyt® Corporation
- Luminex Corporation
- Molecular Devices Inc.
- Pall ForteBio LLC
- PerkinElmer Inc.
- Sigma-Aldrich Corp.
- Tecan Group Ltd.
- Thermo Fischer Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 273 |
| Published | April 2025 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 40.4 Billion |
| Forecasted Market Value ( USD | $ 45.3 Billion |
| Compound Annual Growth Rate | 1.6% |
| Regions Covered | Global |
